Should I Buy PCRX? PCRX 2026 Analysis

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

20.380

1 Day change

2.67%

52 Week Range

27.640

Analysis Updated At

2026/01/26

Pacira Biosciences Inc (PCRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, financial performance shows declining net income and EPS, and there are no significant positive catalysts or strong trading signals to justify immediate action. Holding off for better entry points or additional positive developments is recommended.

Technical Analysis

The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 38.282, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). The price is closer to the support level (S1: 19.272) than resistance (R1: 23.94), indicating limited upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds have significantly increased their buying activity (up 695.83% last quarter). Analysts from H.C. Wainwright are optimistic about the impact of the NOPAIN Act and nerve block approvals, with a $38 price target.

Neutral/Negative Catalysts

No recent news or significant insider trading activity. Financial performance in Q3 2025 shows a sharp decline in net income (-103.79% YoY) and EPS (-103.86% YoY), despite a slight revenue increase (+6.49% YoY). Gross margin improvement (+6.54% YoY) is not sufficient to offset declining profitability. Technical indicators are bearish, and no recent trading signals (AI Stock Picker or SwingMax) are present.

Financial Performance

In Q3 2025, revenue increased by 6.49% YoY to $179.5M, but net income dropped significantly by -103.79% YoY to $5.43M. EPS also fell by -103.86% YoY to $0.12. Gross margin improved to 72.93%, up 6.54% YoY, but profitability remains a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Barclays initiated coverage with an Equal Weight rating and a $27 price target, citing a neutral view on the specialty pharmaceuticals industry. H.C. Wainwright assumed coverage with a Buy rating and a $38 price target, highlighting the positive impact of the NOPAIN Act and nerve block approvals. Analyst sentiment is mixed, with some optimism for long-term growth but no immediate catalysts.

7 Analyst Rating

Wall Street analysts forecast PCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCRX is 29.71 USD with a low forecast of 23 USD and a high forecast of 38 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

1 Sell

Moderate Buy

Current: 19.850

Low

Averages

29.71

High

Current: 19.850

Low

Averages

29.71

High

Barclays

Equal Weight

initiated

$27

AI Analysis

2025-12-08

Reason

Barclays

Price Target

$27

AI Analysis

2025-12-08

initiated

Equal Weight

Reason

Barclays initiated coverage of Pacira with an Equal Weight rating and $27 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

H.C. Wainwright

Buy

initiated

$38

2025-11-17

Reason

H.C. Wainwright

Price Target

$38

2025-11-17

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Pacira with a Buy rating and $38 price target. The firm thinks the enactment of the NOPAIN Act removes any barriers to access in the key surgical procedures in which Pacira's Exparel is best suited. In addition, the approval for nerve blocks should drive consistent clinical performance and removes "technique" sensitivity, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PCRX

Unlock Now

PCRX Should I Buy

PCRX Should I Buy

Should You Buy Pacira Biosciences Inc (PCRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch